Executive Director, US Pricing & Contracting Strategy

Executive Director, US Pricing & Contracting Strategy

1 day ago Be among the first 25 applicants

About Summit Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people.

Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Location:
Princeton, NJ ONSITE

Summit has multiple global Phase 3 clinical studies, including:

• Non-small Cell Lung Cancer (NSCLC)

• HARMONi:
  Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR‑mutated, locally advanced or metastatic non‑squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.
• HARMONi‑3:
  Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first‑line metastatic NSCLC.
• HARMONi‑7:
  Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first‑line metastatic NSCLC.

• Colorectal Cancer (CRC)

• HARMONi‑GI3:
  Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

As a key member of the Market Access leadership team, the Executive Director, US Pricing & Contracting Strategy will lead the development and execution of pricing and contracting strategies to ensure optimal market access and reimbursement. This role demands a strategic leader with profound expertise in the US pricing and reimbursement landscape across all US customer channels, understanding the interconnectivity among various stakeholders.

The individual will be responsible for all aspects of pricing and contracting, including price reporting systems, government price reporting, and contract development.

• Develop and manage robust price reporting systems to ensure accurate and timely reporting of pricing data.
• Oversee government price reporting processes, ensuring compliance with all regulatory requirements and guidelines.
• Manage relationships with outsourced service providers to ensure high‑quality and efficient delivery of pricing and contracting services.
• Average Sales Price (ASP) management, ensuring accurate calculation and reporting to support reimbursement strategies.
• Develop and implement contract modeling strategies to optimize pricing and contracting terms, enhancing market access and profitability.
• Manage contract operations, including rebates and chargebacks, to ensure efficient and compliant processing.
• Lead and facilitate the pricing committee, ensuring alignment on pricing strategies and decisions across the organization.
• Ensure compliance with state pricing transparency requirements, maintaining accurate and up‑to‑date pricing information.
• Develop and maintain a comprehensive archive of price decisions to support strategic planning and compliance.
• Perform all other duties as assigned.

• Bachelor’s degree in Business, Healthcare, or a related field; advanced degree preferred.
• Minimum of 15+ years of experience in pricing and contracting strategy within the pharmaceutical industry, with a focus on oncology and HCP‑administered products; experience/knowledge of ex‑US markets pricing is a plus.
• Proven track record of successful management of price reporting systems and government…